Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee.
Topol EJ, Armstrong P, Van de Werf F, Kleiman N, Lee K, Morris D, Simoons M, Barbash G, White H, Califf RM. Topol EJ, et al. Among authors: van de werf f. J Am Coll Cardiol. 1992 May;19(6):1123-8. doi: 10.1016/0735-1097(92)90312-b. J Am Coll Cardiol. 1992. PMID: 1564212 Free article. Clinical Trial.
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Van de Werf F. Barbash GI, et al. Among authors: van de werf f. J Am Coll Cardiol. 1992 Jul;20(1):36-41. doi: 10.1016/0735-1097(92)90134-9. J Am Coll Cardiol. 1992. PMID: 1607536 Free article. Clinical Trial.
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. Maggioni AP, et al. Among authors: van de werf f. N Engl J Med. 1992 Jul 2;327(1):1-6. doi: 10.1056/NEJM199207023270101. N Engl J Med. 1992. PMID: 1598096 Free article. Clinical Trial.
Relation between previous lipid-lowering therapy and infarct size (creatine kinase-MB level) in patients presenting with acute myocardial infarction.
Aronow HD, Lincoff AM, Quinn MJ, McRae AT, Gurm HS, Houghtaling PL, Granger CB, Harrington RA, Van de Werf F, Topol EJ, Lauer MS; GUSTO IIb and PURSUIT Trial Investigators. Aronow HD, et al. Among authors: van de werf f. Am J Cardiol. 2008 Nov 1;102(9):1119-24. doi: 10.1016/j.amjcard.2008.06.032. Epub 2008 Aug 27. Am J Cardiol. 2008. PMID: 18940276 Clinical Trial.
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Armstrong PW, et al. Among authors: van de werf f. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10. N Engl J Med. 2013. PMID: 23473396 Free article. Clinical Trial.
757 results